Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Adaptiivse kontrollgrupi eksperimentaalne disain× | Adaptiivne randomiseeritud kontrollitud uuring (adaptive RCT)× | |
|---|---|---|
| Valdkond | Katsedisain | Katsedisain |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1994 (formal adaptive framework); wider adoption 2000s–2010s | 1980s–2000s (formalized; earlier sequential testing roots from Wald, 1947) |
| Looja≠ | Peter Bauer and Klaus Kohne (adaptive interim analysis framework, 1994); broader adaptive design methodology developed by Scott Chow and Mark Chang | Donald Berry and others; foundational adaptive trial methods developed through 1980s–2000s biostatistics literature |
| Tüüp≠ | Adaptive experimental design | Experimental design — adaptive variant of RCT |
| Algallikas≠ | Chow, S.-C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman and Hall/CRC. ISBN: 978-1584886760 | Chow, S.-C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman & Hall/CRC. ISBN: 978-1584887690 |
| Rööpnimetused | adaptive controlled experiment, adaptive two-arm controlled design, adaptive parallel-group design, flexible controlled trial design | Adaptive RCT, Response-adaptive RCT, Adaptive clinical trial, Platform trial |
| Seotud≠ | 4 | 6 |
| Kokkuvõte≠ | An adaptive control group experimental design is an experiment that assigns participants to at least one treatment arm and one concurrent control group, while allowing pre-specified modifications to the trial — such as sample size re-estimation, early stopping, or allocation ratio changes — based on accumulating data. Adaptations are governed by decision rules established before the study begins, preserving Type I error control while improving efficiency. | An adaptive randomized controlled trial (adaptive RCT) is an experimental design in which pre-specified rules allow modifications to the trial while it is ongoing — such as changing allocation ratios, dropping underperforming arms, or stopping early for efficacy or futility — based on accumulating interim data. These adaptations are planned before the trial starts and governed by statistical rules to preserve Type I error control and validity. |
| ScholarGateAndmestik ↗ |
|
|